Emma Andrus, Associate Editor

The FDA has added efficacy and safety data for patients ages 12 years and older with uncontrolled moderate-to-severe atopic dermatitis with hand and/or foot involvement.

A recent retrospective cohort study described drug survival and treatment patterns among patients with newly-diagnosed generalized pustular psoriasis.

Additional studies are needed to adopt preventative measures and identify patients who may be deemed "at risk."

Keep up with the latest headlines in dermatology from the past week, including the rising demand for anti-aging products in young patients, eczema and mental health, and more.

ICYMI, this week we had articles about higher response rates were observed in HS patients treated with lutikizumab, a placebo-controlled study of cryosim-1 in prurigo nodularis, industry recommendations for drug products containing benzene, and more.

This is the first known meta-analysis to review the association between extent of smoking androgenetic alopecia.

Among the many sessions to be held at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

The study explored the use of the ointment in an area of 100 cm squared.

Click here to answer our poll.

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.

Researchers found that high levels of AST and ALT in patients with acne taking oral isotretinoin was low in incidence.

Researchers say that application of these findings in clinical settings could enhance treatment optimization.

Researchers said this data is demonstrative of VYN201's positive effects on multiple vitiligo-related biomarkers.

Researchers compared the quality of life, anxiety, depression, sleep disturbance, and other associated factors between patients with alopecia areata and vitiligo.

A randomized, placebo-controlled trial of the selective transient receptor potential melastatin 8 agonist explored its efficacy and safety in PN.

Researchers analyzed the characteristics of Wood's lamp and reflective confocal laser scanning microcopy in guiding vitiligo staging.

Higher response rates were observed in patients treated with lutikizumab. The drug will now advance to phase 3 clinical trials.

A meta-analysis revealed that a post-operative care routine that involves psychological well-being leads to improved patient outcomes.

Keep up with the latest headlines in dermatology from the past week, including a successful year for the Skin of Color Society, a rise in skin clinic visits attributed to carbon monoxide levels, and more.

The approval marks a milestone for patients ages 1 year of age and older who face the persistent, highly contagious condition.

The last patient has been dosed in the trial of the potential first-in-class oncolytic peptide for BCC.

The pilot study explored the use of double-conjugated retinoid serum used in combination with exfoliating peel pads.

The filing is supported by positive phase 3 clinical trial data.

Soligenix shared today positive top-line data stemming from the phase 2a clinical trial.

The Type C meeting held this past December involved discussion of a phase 3 clinical development plan for Ycanth in the treatment of common warts.

Results of this study may also be indicative of oral orismilast's ability to contribute to meaningful clinical improvements, investigators noted.

A late breaking session from Revolutionizing Atopic Dermatitis Virtual Conference analyzed the frequency and clinical meaningfulness of conjunctivitis.

Dermatology Times asked our readers to share what conferences they are looking forward to in the first quarter of 2024.

Click here to answer this week's poll.